555 related articles for article (PubMed ID: 33329600)
1. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
2. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
McKenney AS; Lau AN; Somasundara AVH; Spitzer B; Intlekofer AM; Ahn J; Shank K; Rapaport FT; Patel MA; Papalexi E; Shih AH; Chiu A; Freinkman E; Akbay EA; Steadman M; Nagaraja R; Yen K; Teruya-Feldstein J; Wong KK; Rampal R; Vander Heiden MG; Thompson CB; Levine RL
J Clin Invest; 2018 Feb; 128(2):789-804. PubMed ID: 29355841
[TBL] [Abstract][Full Text] [Related]
3. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
Zhang SJ; Abdel-Wahab O
Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
[TBL] [Abstract][Full Text] [Related]
4. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
5. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
8. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
Fleischman AG; Aichberger KJ; Luty SB; Bumm TG; Petersen CL; Doratotaj S; Vasudevan KB; LaTocha DH; Yang F; Press RD; Loriaux MM; Pahl HL; Silver RT; Agarwal A; O'Hare T; Druker BJ; Bagby GC; Deininger MW
Blood; 2011 Dec; 118(24):6392-8. PubMed ID: 21860020
[TBL] [Abstract][Full Text] [Related]
9. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
10. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
Ramos TL; Sánchez-Abarca LI; Redondo A; Hernández-Hernández Á; Almeida AM; Puig N; Rodríguez C; Ortega R; Preciado S; Rico A; Muntión S; Porras JRG; Del Cañizo C; Sánchez-Guijo F
Oncotarget; 2017 Apr; 8(17):28187-28202. PubMed ID: 28390197
[TBL] [Abstract][Full Text] [Related]
11. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Rao TN; Hansen N; Hilfiker J; Rai S; Majewska JM; Leković D; Gezer D; Andina N; Galli S; Cassel T; Geier F; Delezie J; Nienhold R; Hao-Shen H; Beisel C; Di Palma S; Dimeloe S; Trebicka J; Wolf D; Gassmann M; Fan TW; Lane AN; Handschin C; Dirnhofer S; Kröger N; Hess C; Radimerski T; Koschmieder S; Čokić VP; Skoda RC
Blood; 2019 Nov; 134(21):1832-1846. PubMed ID: 31511238
[TBL] [Abstract][Full Text] [Related]
12. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
14. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic JAK2
Prestipino A; Emhardt AJ; Aumann K; O'Sullivan D; Gorantla SP; Duquesne S; Melchinger W; Braun L; Vuckovic S; Boerries M; Busch H; Halbach S; Pennisi S; Poggio T; Apostolova P; Veratti P; Hettich M; Niedermann G; Bartholomä M; Shoumariyeh K; Jutzi JS; Wehrle J; Dierks C; Becker H; Schmitt-Graeff A; Follo M; Pfeifer D; Rohr J; Fuchs S; Ehl S; Hartl FA; Minguet S; Miething C; Heidel FH; Kröger N; Triviai I; Brummer T; Finke J; Illert AL; Ruggiero E; Bonini C; Duyster J; Pahl HL; Lane SW; Hill GR; Blazar BR; von Bubnoff N; Pearce EL; Zeiser R
Sci Transl Med; 2018 Feb; 10(429):. PubMed ID: 29467301
[TBL] [Abstract][Full Text] [Related]
17. Modeling myeloproliferative neoplasms: From mutations to mouse models and back again.
Morotti A; Rocca S; Carrà G; Saglio G; Brancaccio M
Blood Rev; 2017 May; 31(3):139-150. PubMed ID: 27899218
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasm stem cells.
Mead AJ; Mullally A
Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]